Total Payments
$7,139
2024 Payments
$1,153
Companies
39
Transactions
463
Medicare Patients
6,852
Medicare Billing
$451,222
Payment Breakdown by Category
Food & Beverage$7,139 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,139 | 463 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,358 | 129 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $957.92 | 68 | $0 (2024) |
| Amgen Inc. | $727.00 | 53 | $0 (2024) |
| PFIZER INC. | $531.47 | 42 | $0 (2024) |
| 3B Medical, Inc. | $520.87 | 1 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $360.72 | 21 | $0 (2024) |
| Merck Sharp & Dohme LLC | $359.07 | 19 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $286.41 | 20 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $262.79 | 16 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $206.26 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,153 | 73 | Novartis Pharmaceuticals Corporation ($189.56) |
| 2023 | $1,540 | 70 | 3B Medical, Inc. ($520.87) |
| 2022 | $510.33 | 33 | Merck Sharp & Dohme LLC ($126.91) |
| 2021 | $323.48 | 20 | PFIZER INC. ($91.51) |
| 2020 | $425.96 | 36 | Novartis Pharmaceuticals Corporation ($164.78) |
| 2019 | $1,257 | 93 | Novartis Pharmaceuticals Corporation ($325.80) |
| 2018 | $1,044 | 66 | Novartis Pharmaceuticals Corporation ($257.52) |
| 2017 | $884.33 | 72 | Novartis Pharmaceuticals Corporation ($183.03) |
All Payment Transactions
463 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $13.30 | General |
| Category: Cardiovascular | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $19.05 | General |
| Category: Cardiovascular | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/29/2024 | Abbott Laboratories | ACCENT (Device) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: Cardiac Rhythm Management | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/19/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $17.71 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/15/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: Obesity | ||||||
| 11/13/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: Cardiology | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/06/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $14.46 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: Cardio-renal | ||||||
| 10/24/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: NEUROLOGY | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.74 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $1.29 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $1.03 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.30 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/03/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: Obesity | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $1.42 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $2.78 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $13.95 | General |
| Category: Cardiovascular | ||||||
| 09/24/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $17.70 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 09/23/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,709 | 2,176 | $319,293 | $111,217 |
| 2022 | 14 | 1,977 | 2,492 | $341,362 | $128,316 |
| 2021 | 17 | 1,858 | 2,393 | $409,150 | $130,351 |
| 2020 | 12 | 1,308 | 1,678 | $246,085 | $81,337 |
Total Patients
6,852
Total Services
8,739
Medicare Billing
$451,222
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 303 | 443 | $64,235 | $38,588 | 60.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 378 | 384 | $105,905 | $19,758 | 18.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 124 | 273 | $36,855 | $16,314 | 44.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 70 | 70 | $21,000 | $8,385 | 39.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 78 | 78 | $19,555 | $7,658 | 39.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 48 | 50 | $18,500 | $6,553 | 35.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 359 | 524 | $26,200 | $5,218 | 19.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 88 | 88 | $10,560 | $5,078 | 48.1% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 101 | 101 | $7,070 | $1,605 | 22.7% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 100 | 100 | $5,000 | $1,057 | 21.1% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 30 | 33 | $1,155 | $586.74 | 50.8% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 13 | 14 | $2,898 | $263.48 | 9.1% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 17 | 18 | $360.00 | $151.74 | 42.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 318 | 460 | $66,700 | $41,317 | 61.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 421 | 430 | $62,350 | $23,050 | 37.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 142 | 148 | $54,760 | $22,347 | 40.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 143 | 330 | $44,550 | $17,926 | 40.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 67 | 67 | $20,100 | $7,893 | 39.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2022 | 65 | 65 | $28,795 | $3,839 | 13.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 352 | 487 | $24,350 | $3,694 | 15.2% |
| 93268 | Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring and review and report by health care professional | Office | 2022 | 15 | 15 | $6,450 | $1,978 | 30.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2022 | 208 | 241 | $6,025 | $1,508 | 25.0% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2022 | 88 | 88 | $6,160 | $1,452 | 23.6% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2022 | 88 | 88 | $4,400 | $967.17 | 22.0% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2022 | 40 | 42 | $8,232 | $813.80 | 9.9% |
About Dr. William Denney, MD
Dr. William Denney, MD is a Cardiovascular Disease healthcare provider based in Foley, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760595615.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Denney, MD has received a total of $7,139 in payments from pharmaceutical and medical device companies, with $1,153 received in 2024. These payments were reported across 463 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($7,139).
As a Medicare-enrolled provider, Denney has provided services to 6,852 Medicare beneficiaries, totaling 8,739 services with total Medicare billing of $451,222. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease
- Location Foley, AL
- Active Since 08/16/2006
- Last Updated 01/05/2017
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1760595615
Products in Payments
- ENTRESTO (Drug) $961.34
- XARELTO (Drug) $957.92
- LUNA (Device) $520.87
- ELIQUIS (Drug) $518.81
- Corlanor (Drug) $439.62
- LEQVIO (Drug) $396.58
- VERQUVO (Drug) $359.07
- Repatha (Biological) $287.38
- LifeVest (Device) $286.41
- MULTAQ (Drug) $254.22
- PRALUENT ALIROCUMAB INJECTION (Biological) $153.57
- PRADAXA (Drug) $130.55
- CHANTIX (Drug) $122.99
- GIAPREZA (Drug) $113.85
- JARDIANCE (Drug) $113.61
- UPTRAVI (Drug) $112.74
- PRALUENT (Drug) $106.50
- SAMSCA (Drug) $90.08
- Inpefa (Drug) $82.02
- FLOWTRIEVER CATHETER, S (Device) $63.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.